American Association for Cancer Research

Program

MONDAY, OCTOBER 22


REGISTRATION
10:00 a.m.-8:00 p.m.

EDUCATIONAL SESSION 1: PREDICTIVE BIOMARKERS AND FUNCTIONAL IMAGING AS AIDS TO DRUG DEVELOPMENT
1:30 p.m.-3:30 p.m.
Chairperson: Julius Leyton, Imperial College London, London, England

PET Tracers as Biomarkers in Oncology Drug Development
Julius Leyton

Pharmacogenomic Applications in Oncology Drug Development
Nicholas C. Dracopoli, Bristol-Myers Squibb Company, Princeton, NJ, USA

Functional Imaging as Aids to Drug Development
Patricia M. Price, Christie Hospital NHS Trust, Manchester, England

EDUCATIONAL SESSION 2: MICRO AND INTERFERING RNAS IN DISEASE CAUSATION, TARGET VALIDATION, AND CANCER TREATMENT
3:30 p.m.-5:30 p.m.
Chairperson: Frank Slack, Yale University, New Haven, CT, USA

MicroRNAs in Cancer
Frank Slack

MicroRNAs in the Response to Cancer Therapy
Joanne B. Weidhaas, Yale University School of Medicine, New Haven, CT, USA

Toward a Non-Coding RNA Revolution in the Cancer Society
George A. Calin, UT M. D. Anderson Cancer Center, Houston, TX, USA

miRNAs as Oncogenes, Tumor Suppressors, and Therapeutic Intervention Points
David Brown, Asuragen, Inc., Austin, TX, USA

OPENING RECEPTION
6:00 p.m.-7:30 p.m.


TUESDAY, OCTOBER 23


OPENING REMARKS
8:00 a.m.-8:05 a.m.

KEYNOTE ADDRESSES
8:05 a.m.-10:05 a.m.

Molecular Profiling and Breast Cancer: Towards Better Risk Estimation, Prognostication, and Prediction
Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Oslo, Norway

Discovery of Disease Alleles and Drug Targets in Myeloid Leukemias
Dwight Gary Gilliland, Harvard Medical School, Boston, MA, USA

PLENARY SESSION 1: CANCER STEM CELLS
10:30 a.m.-12:30 p.m.
Session Chairperson: Peter B. Dirks, Hospital for Sick Children, Toronto, ON, Canada

Brain Tumor Stem Cells: Chemical Determinants of Self Renewal
Peter B. Dirks

Examining the Role of Stem Cell Biology in Lung Cancer
Carla Kim, Children's Hospital, Boston, MA, USA

Characterization and Targeting of Human Leukemia Stem Cells
Craig T. Jordan, University of Rochester School of Medicine, Rochester, NY, USA

Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma
Laurie Ailles, Stanford University School of Medicine, Palo Alto, CA, USA

POSTER SESSION A / EXHIBITS
12:30 p.m.-2:30 p.m.

PLENARY SESSION 2: TARGETING DNA REPAIR PATHWAYS
2:30 p.m.-4:30 p.m.
Chairperson: Alan Ashworth, Institute of Cancer Research, London, England

DNA Damage-Activated Kinases as Targets for Cancer Therapy
Roger J. Griffin, University of Newcastle upon Tyne, Newcastle upon Tyne, England

Targeting Fanconi Anemia / BRCA Pathway Defects in Cancer Therapeutics
Alan D. D'Andrea, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Right Silencing and Stratified Therapy in Glioblastoma
Monika E. Hegi, University Hospital, Lausanne, Switzerland

ERCC1 as Relevant Targets in the DNA Repair Pathway
Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France

PROFFERED PAPER SESSION 1
4:30 p.m.-5:30 p.m.

POSTER SESSION A (CONTINUED) / EXHIBITS
5:30 p.m.-7:30 p.m.


WEDNESDAY, OCTOBER 24


PLENARY SESSION 3: EPIGENETIC TARGETS
8:00 a.m.-10:00 a.m.
Chairperson: Kristian Helin, University of Copenhagen, Copenhagen, Denmark

Histone Methyltransferases and Demethylases in Cell Proliferation and Cancer
Kristian Helin

Title to be announced
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD, USA

The Cancer Epigenome
Peter A. Jones, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Chromatin Alterations in Leukemias
Pier Giuseppe Pelicci, European Institute of Oncology, Milan, Italy

PLENARY SESSION 4: GENOME-WIDE APPROACHES TO DIAGNOSIS, STRATIFICATION, AND TARGET IDENTIFICATION
10:30 a.m.-12:30 p.m.
Chairperson: Louis M. Staudt, National Cancer Institute, Bethesda, MD, USA

Cancer Genetic Markers of Susceptibility: Genome-wide Association Studies in Breast and Prostate Cancer
Stephen Chanock, National Cancer Institute, Bethesda, MD, USA

Predicting Effectiveness and Understanding Resistance to Targeted Inhibitors: Lessons from EGFR in Lung Cancer
Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA, USA

Mechanisms of Resistance to NOTCH1 Inhibitors in T-ALL
Adolfo Ferrando, Columbia University Medical Center, New York, NY, USA

From Genomic Diversity to Tumor Dependency in Human Cancer
Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA

POSTER SESSION B / EXHIBITS
12:30 p.m.-2:30 p.m.

CONCURRENT SESSIONS 1 - 4
2:30 p.m.-4:30 p.m.

  • HIGH THROUGHPUT SCREENS FOR TARGET IDENTIFICATION
    Chairperson: René Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands

    • Biomarkers of Resistance to Cancer Therapy Discovered through Functional Genetic Screens
      René Bernards
    • Functional Genomics of Chemosensitivity Exposes Deviant Cancer Cell Regulatory Systems
      Michael A. White, University of Texas Southwestern Medical Center, Dallas, TX, USA
    • Achilles Heel RNA Interference Screens for Molecular Targets in Cancer
      Louis M. Staudt, National Cancer Institute, Bethesda, MD, USA
    • Using Cellular Pharmacogenomics to Identify and Prioritize Genetic Determinants of Drug Response
      Jeffrey M. Trent, Translational Genomics Research Institute, Phoenix, AZ, USA
  • SMALL MOLECULE APPROACHES TO THE REGULATION OF APOPTOSIS
    Chairperson: Louis J. Lombardo, Bristol-Myers Squibb Company, Princeton, NJ, USA

    • Design of Small-molecule SMAC Mimetics as Apoptosis Inducers in Tumor Cells: Molecular Insights into Apoptosis Regulation
      Shaomeng Wang, University of Michigan, Ann Arbor, MI, USA
    • Drugging “Undruggable” Targets
      Gregory L. Verdine, Harvard University, Cambridge, MA, USA
    • Structure-based Design of IAP Antagonists
      Wayne J. Fairbrother, Genentech, Inc., South San Francisco, CA, USA
    • Apoptosis Based Therapies from a Medicinal Chemistry Perspective
      Maurizio Pellecchia, The Burnham Institute, La Jolla, CA
  • TUMOR MICROENVIRONMENT AND METASTASIS
    Chairperson: Valerie M. Weaver, University of California, San Francisco, CA, USA

    • Spatial-Mechanical Cues from the Microenvironment Modulate Malignant Transformation and Treatment Efficacy
      Valerie M. Weaver
    • Molecular Mechanisms Promoting Tumor Metastasis to Lymph Nodes and Beyond
      Judith A. Varner, University of California San Diego Cancer Center, La Jolla, CA, USA
    • Cancer Therapeutic Agents Act Directly on Targets in the Microenvironment
      Michael B. Sporn, Dartmouth Medical School, Hanover, NH, USA
    • Lymphatic Metastasis: How Tumor Cells Find the Best Escape Route
      Melody Swartz, Ecole Polytechnique Federale de Lausanne School of Life Sciences, Lausanne, Switzerland
  • EMERGING KINASE TARGETS
    Chairperson: Judith S. Sebolt-Leopold, Ann Arbor, MI, USA

    • Genetic Predictors of MAP Kinase Dependence
      David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Targeting the IGF Receptor as Treatment for Cancer
      V. M. Macaulay, Weatherall Institute of Molecular Medicine, Oxford, England
    • Exploiting the Kinome to Target Cell Cycle Regulation
      Michelle D. Garrett, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    • Cell Growth Control by mTORC1 and S6K Signaling
      John Blenis, Harvard Medical School, Boston, MA

PROFFERED PAPER SESSION 2
4:30 p.m.-5:30 p.m.

POSTER SESSION B (CONTINUED) / EXHIBITS
5:30 p.m.-7:30 p.m.


THURSDAY, OCTOBER 25


PLENARY SESSION 5: TUMOR IMMUNOLOGY
8:00 a.m.-10:00 a.m.
Chairperson: James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Immune Checkpoint Blockade in Cancer Therapy
James P. Allison

Regulating Regulatory T Cells: A Novel Strategy to Augment Anti-tumor Immunity
Bernard A. Fox, Earle A. Chiles Research Institute, Portland, OR, USA

Failure at the Effector Phase: Immune Resistance in the Tumor Microenvironment
Thomas Frank Gajewski, University of Chicago, Chicago, IL, USA

Immunogenicity of Cytotoxic Drugs: Molecular Bases and Clinical Implementation
Laurence Zitvogel, Institut Gustave-Roussy, Villejuif, France

PLENARY SESSION 6: TOWARDS PERSONALIZED CANCER THERAPY (TALKS AND PANEL DISCUSSION)
10:30 a.m.-12:30 p.m.
Chairperson: Tona M. Gilmer, GlaxoSmithKline, Research Triangle Park, NC, USA

Molecular Diagnostics: A Need to Improve Cancer Care
Laura J. van't Veer, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Integrated Genomic Test to Aid Treatment Selection
Lajos Pusztai, UT M.D. Anderson Cancer Center, Houston, TX, USA 

Optimizing Therapy through Pharmacogenomics
Kathleen D. Danenberg, Response Genetics, Inc., Los Angeles, CA, USA

HER2/neu- A Practical Example
Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Panel Discussion

POSTER SESSION C / EXHIBITS
12:30 p.m.-2:30 p.m.

CONCURRENT SESSIONS 5 - 8
2:30 p.m.-4:30 p.m.

  • CANCER CELL METABOLISM
    Chairperson: Craig B. Thompson, University of Pennsylvania, Philadelphia, PA, USA

    • Therapeutic Targeting of Cancer Cell Metabolism
      Craig B. Thompson
    • Cancer Cell Metabolism in the Crosshairs: Targeting the mTOR Pathway for Cancer Therapy
      Robert T. Abraham, Wyeth Pharmaceuticals, Pearl River, NY, USA
    • Targeting Survivin in Cancer Therapy: Fulfilled Promises and Open Questions
      Nadia Zaffaroni, Istituto Nazionale Tumori, Milan, Italy
    • Role of the MZ Splice Isoform of Pyruvate Kinase in Aerobic Glycolysis and Tumorigenesis
      Heather Christofk, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
  • RATIONAL DRUG COMBINATIONS
    Chairperson: Roman Perez-Soler, Montefiore Medical Center, Bronx, NY, USA

    • Synergistic Schedules with Combinations of EGFR Inhibitors and Cytotoxic Agents
      Roman Perez-Soler
    • Epigenetic Therapies: What's the Target?
      Steven D. Gore, Johns Hopkins University, Baltimore, MD, USA
    • Combinations with Angiogenesis Inhibitors
      John V. Heymach, UT M. D. Anderson Cancer Center, Houston, TX, USA
    • Multi-targeted Suppression of the RAS-AKT Signaling Network in NSCLC
      Hayley M. McDaid, Albert Einstein College of Medicine, Bronx, NY, USA
  • PROTEIN STABILITY AND TURNOVER
    Chairperson: Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY. USA

    • Hsp90-dependent Protein Folding as a Therapeutic Target in Cancer
      Neal Rosen
    • Novel Discovery of MLN4924, a Novel, First in Class nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer
      Mark Rolfe, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA
    • Regulation of hsp90 Chaperone Activity by Acetylation
      Leonard M. Neckers, National Cancer Institute, Rockville, MD, USA
    • Exploiting Molecular Chaperone Addiction in Cancer: New Drugs and Biomarkers
      Paul Workman, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
  • RE-ENGINEERING TUMOR SUPPRESSION
    Chairperson: Karen H. Vousden, Beatson Institute for Cancer Research, Glasgow, Scotland

    • The p53 Tumor Suppressor as a Therapeutic Target
      Karen H. Vousden
    • Overcoming the Loss of Mitochondrial Tumor Suppressors by Reactivating HIF Prolyl Hydroxylases
      Eyal Gottlieb, Beatson Institute for Cancer Research, Glasgow, Scotland
    • Targeting Bcl-2 Family Proteins to Treat Cancer
      Steven W. Elmore, Abbott Laboratories, Abbott Park, IL, USA
    • Synthetic Lethal Approaches to the Treatment of Cancers with DNA Repair Defects
      Alan Ashworth, Institute of Cancer Research, London, England

PROFFERED PAPER SESSION 3
4:30 p.m.-5:30 p.m.

POSTER SESSION C (CONTINUED) / EXHIBITS
5:30 p.m.-7:30 p.m.


FRIDAY, OCTOBER 26


PLENARY SESSION 7: THERAPEUTIC POTENTIAL OF DEVELOPMENTAL GENES
8:00 a.m.-10:00 a.m.
Chairperson: Jon C. Aster, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Targeting Notch in Cancer: Challenges and Opportunities
Jon C. Aster

Novel Molecular Targets in Breast Cancer Progression
Lewis A. Chodosh, University of Pennsylvania, Philadelphia, PA, USA

Notch 1 Inhibitors in Mouse T-ALL Models
Michelle A. Kelliher, University of Massachusetts Medical School, Worcester, MA, USA

Targeting Notch Signaling in Cancer
Christian W. Siebel, Genentech, Inc., South San Francisco, CA, USA

PLENARY SESSION 8: NEW CLINICAL TRIAL DESIGN (TALKS AND PANEL DISCUSSION)
10:30 a.m.-12:30 p.m.
Chairperson: James H. Doroshow, National Cancer Institute, Bethesda, MD, USA

Potential Utilities of the Study of Circulating Tumor Cells in the Design of Clinical Trials of Molecularly Targeted Drugs
Johann S. de Bono, Royal Marsden Hospital, Institute for Cancer Research, Sutton, Surrey, England

New Concepts in Phase II Design
Mark J. Ratain, University of Chicago, Chicago, IL, USA

Clinical Trial Designs for Early Drug Development
James A. Zwiebel, National Cancer Institute, Rockville, MD, USA

Title to be announced
Francesco Pignatti, The European Medicines Agency, London, England

CLOSING CEREMONY
12:30 p.m-12:45 p.m.

DEPARTURE